Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.48 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.46 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.38 |
| ▸ | LPL | P06858 | 1/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5840438 | 0.83 | PDCD1 (0.52) | GABRA1GABRB2LIPGENPP2PDCD1 | |
| SCHEMBL12707641 | 0.80 | LIPG (0.37) | GABRA1GABRB2LIPGLPL | |
| SCHEMBL29468961 | 0.79 | LIPG (0.61) | GABRA1GABRB2LIPGLPLENPP2 | |
| SCHEMBL410387 | 0.79 | LIPG (0.61) | GABRA1GABRB2LIPGLPLENPP2 | |
| SCHEMBL1762931 | 0.78 | GABRA1 (0.48) | GABRA1GABRB2LIPGLPLENPP2 | |
| SCHEMBL599099 | 0.78 | GABRA1 (0.57) | GABRA1GABRB2NLRP3PDCD1CD274 | |
| SCHEMBL16576671 | 0.78 | LIPG (0.38) | GABRA1GABRB2LIPGENPP2PDCD1 | |
| SCHEMBL15536431 | 0.77 | GABRA1 (0.46) | GABRA1GABRB2LIPGLPLDAO | |
| SCHEMBL3793136 | 0.77 | GABRA1 (0.46) | GABRA1GABRB2LIPGLPLENPP2 | |
| Ammonia Solution, Strong SCHEMBL9357829 | 0.76 | GABRA1 (0.55) | GABRA1GABRB2NLRP3PDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018166-A1 | SULFONYL UREA NLRP3 INFLAMMASOME INHIBITORS | VenatoRx Pharmaceuticals, Inc. | 2024-01-18 | — | — | US | disclosed |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | GABRA1 991/4885GABRB2 561/4885LIPG 3010/4885 |
| US-20240018166-A1 | SULFONYL UREA NLRP3 INFLAMMASOME INHIBITORS | NLRP3, PYCARD, NOD1 | GABRA1 3475/4885GABRB2 2168/4885LIPG 1562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.